Talene A. Yacoubian

This study shows that Rab27b knockout worsens alpha-synuclein pathology in mouse models of Parkinson's disease.

This study shows Rab27b enhances lysosomal function and reduces alpha-synuclein accumulation in neurons, suggesting it as a therapeutic target for synucleinopathies.

This paper shows that combined Alzheimer's and Parkinson's protein pathologies enhance neuroinflammation and neurodegeneration in a mouse model.

The paper measures LRRK2 kinase activity via pT73-Rab10 in serum, linking it to inflammation and Parkinson's disease severity.

This study shows that phosphorylation of 14-3-3{theta} at S232 reduces its ability to inhibit LRRK2 kinase activity, particularly for G2019S LRRK2, but not for R1441G LRRK2.

This study shows that 14-3-3{theta} reduces alpha-synuclein toxicity and aggregation in an in vivo preformed fibril model, improving behavioral and neuronal outcomes.

This study shows Rab27a/b knockout prevents alpha-synuclein aggregation, toxicity, and cell-to-cell transmission in vitro and in vivo.

This study shows Rab27b regulates alpha-synuclein release, autophagic clearance, and toxicity, linking it to synucleinopathy pathogenesis.